Introduction: What they say
Noble laureate in Physiology/Medicine (1975) Prof. David Baltimore, from California Institute of Technology, California, USA, had reported in the July 8, 2014 issue of the Journal “Blood” that: “Dual mechanisms by which MiR-125b represses IRF4 to induce myeloid/B-cell leukemias.”
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for Human Leukemias: Gentian Violet, isolated from Gentianopsis Crinita, suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4
From Research findings to Therapeutic opportunity:
This study suggests that Gentian Violet, by increasing the expression of its target gene, it may increase the expression of a number of tumor suppressor genes, including IRF4. Thereby, it could inhibit the progression of B-Cell and myeloid leukemias (fig. 1).
Taken together, this study suggests that pharmacological formulations encompassing “Gentian Violet or its analogues or Gentian Violet in combination with other anticancer drugs“ may be used to inhibit B-Cell and myeloid leukemias.
Details of the research details:
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How Gentian Violet increases the expression of IRF4?
Amount: $ 100
For purchase and payment details, you may reach us at firstname.lastname@example.org
# Research cooperation
Citation: Boominathan, L., Natural product-derived therapy for Human Leukemias: Gentian Violet, isolated from Gentianopsis Crinita, suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 27/February/2017, 5.38 am, Genome-2-Bio-Medicine Discovery Center.
Courtesy: When you cite drop us a line at email@example.com